Right now, every PV vendor is making the same promise. AI will cut your costs by 50 percent. Efficiency gains of 65 percent. Automated case processing that pays for itself in a quarter. Sponsors are hearing these numbers constantly, and the comparison has become harder to make: a monthly vendor fee against a projected AI savings figure that hasn’t been validated at scale, run by a team that may be fully offshore and built around a different staffing model than the one you’re used to.
The efficiency gains are real, for some use cases. What they don’t answer is the question sponsors should be asking first: what happens when something goes wrong?
The Hidden Cost Categories Sponsors Rarely Price In
Three cost categories rarely show up in a vendor proposal, and all three are real. Here’s a framework you can take into your own internal conversations, whoever you’re evaluating.
Remediation cost: what happens when something is wrong
Submission failures. Missed deadlines. Regulatory inspections findings. Reprocessing backlogs. These carry real dollar consequences whether the underlying error was human or AI-generated. What does it cost to unwind a year of substandard PV, and who absorbs that cost when it happens?
Transition cost: the true price of switching
Switching to a 100 percent offshore model doesn’t reduce your oversight burden; it increases it. Less proximity, less reactivity, less flexibility means more internal time spent managing the vendor relationship rather than the program itself. The same is true on the technology side: moving to an AI-assisted platform mid-program means a re-qualification audit, technology validation, and workflow change management layered on top of standard knowledge transfer. Either way, it’s a multi-quarter disruption, not a line item. Worth asking any vendor on an early-2027 adopter timeline what implementation looks like for a program that’s already live.
Regulatory risk cost: the cost of a non-compliance finding
The EU AI Act’s strictest requirements for high-risk AI systems take effect August 2026. Vendors are selling AI-driven PV tools into a compliance environment where the regulatory framework isn’t fully settled yet. A sponsor whose EU programs run through an AI tool without a clear high-risk classification carries a risk that won’t appear on any vendor proposal.
Four Questions to Ask Any Vendor
- What is your regulatory submission compliance rate, and can you show it over time?
Full program compliance across all submissions and years, not a single pilot window.
- Has your program been through a health authority inspection, and what was the outcome?
Many platforms at scale haven’t yet been through an FDA or EMA inspection in their current form. Worth knowing before you sign.
- Where does governance sit in your model, and who makes the medical call?
This is a governance question, not a staffing question. Who is accountable for the clinical judgment behind the output?
- What happens when non-compliance gets it wrong, and can I speak to a client who experienced that?
Ask about a specific error and how it was caught and corrected. General quality assurance language isn’t an answer.
What It Looks Like When Quality Holds
UBC isn’t anti-AI. AI-driven efficiency gains are real for certain tasks, including case narrative generation. What doesn’t change is the quality standard those outputs are held to, and that standard is the actual differentiator, not the tools used to get there.
UBC has maintained a greater than 99 percent regulatory submission compliance rate, year over year, since 2022. That’s a sustained operational standard, not a pilot result. Since 2012, UBC offices have been through four FDA inspections with zero Form 483 observations: programs that have faced external health authority scrutiny, not just internal validation.
UBC doesn’t run a fully offshore staffing model. Where we use a hybrid structure, the offshore and global delivery resources sit under UBC oversight, not outside it. Experienced safety physicians and SMEs review that work, and the operational and project management point of contact stays close to the client and in a compatible time zone. The team accountable for a program is the team UBC puts in front of you, not a layer removed from it.
Reframe the Decision
Efficiency gains are coming for everyone. The question isn’t whether AI and offshore resources reduce case processing time. It does. The real question is what you’re paying for beyond the processing.
Apply the four questions above to any vendor you’re evaluating. They’re the right questions no matter what answer you get back.
If you’d like to talk through how UBC approaches program quality in a changing technology and staffing landscape, we’re glad to have that conversation.
About UBC
United BioSource LLC (UBC) is the leading provider of evidence development solutions with expertise in uniting evidence and access. UBC helps biopharma mitigate risk, address product hurdles, and demonstrate safety, efficacy, and value under real-world conditions. UBC leads the market in providing integrated, comprehensive clinical, safety, and commercialization services and is uniquely positioned to seamlessly integrate best-in-class services throughout the lifecycle of a product.
About the Authors
Mallorie Clement, DiplPharm, PhD, Senior Director, Global Head of Case Processing
Mallorie Clement, DiplPharm, PhD joined UBC in October 2004, as a Drug Safety Officer and was promoted to positions of increasing responsibility. Dr. Clement has been involved in the management of safety data (e.g., clinical trials and spontaneous sources, including case narrative/evaluation, and navigating data within safety databases), literature review, and has gained experience in project management, team management, overseeing the implementation of cross-functional projects. Dr. Clement currently manages the Global Case Processing function which includes case processing, literature review, global submissions, and business requirements.
Prior to joining UBC, Dr. Clement worked as a Research Associate at the Hôpitaux Universitaires de Genève performing research in Cytochrome P450 and p-Glycoprotein phenotyping.
Dr. Clement holds a Federal Pharmacist Diploma from the University of Geneva (Switzerland) and a PhD in clinical pharmacology and later graduated as a university professional in pharmaceutical medicine in the University of Basel.
Tom Coles, Director, Pharmacovigilance
Tom Coles, Director, Pharmacovigilance, has over 10 years’ experience in the pharmacovigilance industry, Tom has overseen case processing teams in pharma and CRO settings, managed client PV systems and projects, authored aggregate reports across multiple indications, serves as the product expert for signal risk management and represented PV for business development activities. Tom is specialized in helping Chinese pharma companies enter the global market, ensuring their PV Systems are fit-for-purpose. At UBC, Tom is part of the PV leadership team and leads the Process Excellence function which manages and maintains client PSMFs, as well as the coordination of PV process documents, compliance, regulatory intelligence, and safety incident reports.
